In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa.

ABSTRACT:

Background

The prevalence of antibiotic resistance is increasing, and multidrug-resistant Pseudomonas aeruginosa has been identified as a serious threat to human health. The production of β-lactamase is a key mechanism contributing to imipenem resistance in P. aeruginosa. Relebactam is a novel β-lactamase inhibitor, active against class A and C β-lactamases, that has been shown to restore imipenem susceptibility. In a series of studies, we assessed the interaction of relebactam with key mechanisms involved in carbapenem resistance in P. aeruginosa and to what extent relebactam might overcome imipenem non-susceptibility.

Results

Relebactam demonstrated no intrinsic antibacterial activity against P. aeruginosa, had no inoculum effect, and was not subject to efflux. Enzymology

SUBMITTER: Young K 

PROVIDER: S-EPMC6610938 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature